文献速递中毒与环境急症

新型合成大麻素AMB-FUBINACA与EMB-FUBINACA致死性中毒一例

Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA.
PubMed 文献 · Clin Toxicol (Phila) · 2019-02-26
一句话结论致命性合成大麻素中毒者血中可检测不到原体,仅查血可能漏诊,须加做其他尸检材料毒物分析。

本文报告一例27岁男性死于急性呼吸衰竭的病例,尸检见内脏淤血、肺水肿和左侧胸膜粘连。尸检材料经乙腈沉淀后LC-MS/MS定量分析,AMB-FUBINACA和EMB-FUBINACA在所有尸检材料中均检出并定量,唯独血液中未检出;固体组织浓度分别为0.2-0.9 ng/g和0.2-3.5 ng/g,胃内容物浓度最高(分别为5.8和36.2 ng/mL)。作者认为这提示两种物质可能为口服摄入、可能参与死亡,且仅分析血样可能无法确认中毒。

要点

  • 致死性合成大麻素中毒者血液中可检测不到原体,仅查血可能无法确认中毒。
  • 本病例AMB-FUBINACA与EMB-FUBINACA在所有尸检材料中检出并定量,唯独血液中未检出。
  • 固体组织中AMB-FUBINACA浓度为0.2-0.9 ng/g,EMB-FUBINACA为0.2-3.5 ng/g。
  • 胃内容物中浓度最高:AMB-FUBINACA 5.8 ng/mL,EMB-FUBINACA 36.2 ng/mL。
  • 作者认为浓度结果可能提示口服摄入,两种物质可能参与死亡。

适用人群与场景

  • 疑似合成大麻素中毒的猝死或死亡病例,需进行尸检毒物分析者

红旗征与不能漏的情况

  • 血液中检测不到合成大麻素原体时,不能据此排除中毒,需同时分析其他尸检材料(如胃内容物、固体组织)。
  • 作者认为AMB-FUBINACA与EMB-FUBINACA使用对健康危险,可能导致致死性中毒。

研究设计与关键结果

  • 病例报告:27岁男性被发现死于公寓床上;尸检见内脏淤血、肺水肿和左侧胸膜粘连,法医结论为急性呼吸衰竭死亡。
  • 尸检材料(血、尿、肝、肾、胃、肠、肺、脑)经乙腈沉淀后LC-MS/MS定量分析。
  • AMB-FUBINACA与EMB-FUBINACA在所有尸检材料中检出并定量,唯独血液中未检出。
  • 固体组织中AMB-FUBINACA浓度为0.2-0.9 ng/g,EMB-FUBINACA浓度为0.2-3.5 ng/g。
  • 胃内容物中浓度最高:AMB-FUBINACA 5.8 ng/mL,EMB-FUBINACA 36.2 ng/mL。

证据类型、等级与局限

  • 证据类型:病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,即使严重或致死性中毒者血液中也可能检测不到合成大麻素,仅分析血样可能无法确认中毒;本病例提示AMB-FUBINACA与EMB-FUBINACA使用对健康危险,可能导致致死性中毒。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: Synthetic cannabinoids are currently the largest group of new psychoactive substances. Those that have been subjected to legal control are replaced by newer uncontrolled substances, which causes constant and dynamic changes to the drug market. Some of the most recent synthetic cannabinoids that have appeared on the "legal highs" market are AMB-FUBINACA and EMB-FUBINACA. Case history: A 27-year-old man was found dead on a bed in an apartment. At autopsy, congestion of internal organs, pulmonary oedema and left-sided pleural adhesions were found. The medical examiner concluded that the man died due to acute respiratory failure. The autopsy materials (blood, urine, liver, kidney, stomach, intestine, lung and brain) were collected for further toxicological analyses. Methods: The synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA were isolated from autopsy materials by precipitation with acetonitrile. The quantitative analyses were carried out by LC-MS/MS. Results: AMB-FUBINACA and EMB-FUBINACA were detected and quantified in all post-mortem materials except the blood. The determined concentrations of these compounds in solid tissues were in the range of 0.2-0.9 ng/g and 0.2-3.5 ng/g. The highest concentrations of AMB-FUBINACA and EMB-FUBINACA were revealed in the stomach content (5.8 and 36.2 ng/mL, respectively). Discussion: The presented case demonstrates that even in cases of fatalities, it is possible that the parent substance will not be present in the blood, while being present in other autopsy materials. The determined concentrations of the compounds may indicate oral administration of synthetic cannabinoids. It can also be assumed that AMB-FUBINACA and EMB-FUBINACA probably contributed to death. Conclusion: The presented case shows that synthetic cannabinoids can be undetected in the blood of even seriously or fatally intoxicated people. This situation means that the analysis of only blood samples may not confirm poisoning. The presented case also suggests that AMB-FUBINACA and EMB-FUBINACA use is dangerous to health and may lead to fatal intoxication.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Adamowicz P, Meissner E, Maślanka M, et al. Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA. Clin Toxicol (Phila). 2019. PMID: 30806094. doi:10.1080/15563650.2019.1580371

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。